Selection of inflationary and tissue-resident T cells during MCMV infection
MCMV 感染期间膨胀和组织驻留 T 细胞的选择
基本信息
- 批准号:8651139
- 负责人:
- 金额:$ 18.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-01-01 至 2018-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntigensBlood CirculationBone MarrowCellsChimera organismCytomegalovirusCytomegalovirus InfectionsDataDevelopmentDiseaseEconomic InflationEnvironmentEpitheliumEquilibriumFaceFetusGenesGlandGoalsGrowthHIVHerpesviridaeHerpesviridae InfectionsHumanHuman MilkImmuneImmunityImmunodominant AntigensImmunologic SurveillanceInfectionInstitute of Medicine (U.S.)IntegrinsKnowledgeLifeMaintenanceMalignant NeoplasmsMammary glandMeasuresMemoryModelingMucous MembraneMusOVA-8OvalbuminPopulationPositioning AttributePredispositionPregnant WomenProcessRoleSalivary GlandsSeriesSiteSpleenSurfaceSystemic infectionT memory cellT-Cell ReceptorT-LymphocyteTestingTherapeuticTimeTissuesTransgenic OrganismsVaccine DesignVaccinesVariantViralViral AntigensVirusVirus LatencyVirus SheddingWorkcytokineemergency service respondermucosal sitenovelnovel vaccinespathogenpressurepreventpublic health relevancepupreactivation from latencyrecombinant virusresearch studytherapy designtooltransmission process
项目摘要
Abstract: Cytomegalovirus (CMV) is a ubiquitous herpesvirus that establishes a systemic, persistent infection.
CMV rarely causes serious disease in humans because systemic, life-long immune surveillance keeps the
virus in check. In fact, CMV stimulates the largest known T cell populations in the circulation of humans. These
T cells accumulate over time in a process called "memory inflation" and control CMV by shutting down viral
reactivation from latency. For these reasons, CMV may serve as a tool for new vaccines against diseases such
as cancer and HIV. However, CMV can cause devastating disease in a developing fetus when the virus is
transmitted to a pregnant woman. Thus, a vaccine to prevent CMV transmission is rated as a highest priority
by the Institute of Medicine. Understanding immune surveillance at sites of viral shedding will be key to
preventing transmission and CMV disease. Recent work has shown that a T cell population called "resident
memory" T cells (TRM) are established at sites in the body that may face viral reactivation. Indeed, TRM cells
may help control herpesvirus reactivation. However, there have been no studies of CMV-specific TRM cells.
Using the natural mouse herpesvirus, murine (M)CMV, our data show that many MCMV-specific TRM cells
developed in the salivary and mammary glands - two sites from which HCMV and MCMV are known to be
shed. More broadly, the salivary and mammary glands are two sites from which several human herpesviruses
are shed. The ontogeny and function of TRM cells is poorly defined, and this gap is critical because these T
cells are best positioned and possibly critical for controlling herpesvirus reactivation. Moreover, the promotion
of such "first responders" - cells positioned at the site of pathogen invasion - is the major advantage of CMV-
vectored vaccines. Aim 1: We will determine whether MCMV-specific TRM cells control viral latency and
whether vaccines that elicit TRM formation will limit viral replication. Aim 2: Both repeated antigen recognition
and the local cytokine environment are thought to modulate TRM development. Critically, infection with a
spread-defective ¿gL-MCMV, which can not spread to the salivary gland, increased the formation of salivary
gland MCMV-specific TRM cells, implying that viral replication or repeated antigen recognition by T cells
antagonizes TRM development. We will distinguish between these possibilities using a series of recombinant
viruses. Aim 3: Our preliminary data show that memory inflation in circulation is driven by a competition for viral
antigen. T cells that successfully compete, inflate; those that fail to compete do not. Remarkably, our data
suggest that MCMV-specific TRM cells were enriched for T cells that do not undergo memory inflation. Thus, we
will determine whether T cells that fail to compete for MCMV antigen are preferentially enriched in the TRM pool.
Together, these experiments will determine the ontogeny and function of MCMV-specific TRM cells that reside
at these critical mucosal sites of herpesvirus shedding.
翻译后摘要:巨细胞病毒(CMV)是一种普遍存在的疱疹病毒,建立一个系统的,持续的感染。
CMV很少在人类中引起严重的疾病,因为全身性的、终身的免疫监视使巨细胞病毒在体内保持稳定。
病毒检查事实上,CMV刺激人类循环中最大的已知T细胞群。这些
T细胞在一个称为“记忆膨胀”的过程中随着时间的推移而积累,并通过关闭病毒来控制CMV
从潜伏期重新激活。由于这些原因,CMV可以作为一种工具,用于针对疾病的新疫苗,
癌症和艾滋病然而,当病毒感染时,CMV可在发育中的胎儿中引起毁灭性疾病。
传染给孕妇。因此,预防CMV传播的疫苗被列为最优先事项
由医学研究所。了解病毒脱落部位的免疫监视将是
预防传播和CMV疾病。最近的研究表明,一种称为“居民”的T细胞群,
记忆性T细胞(TRM)在体内可能面临病毒再活化的部位建立。事实上,TRM细胞
可能有助于控制疱疹病毒的重新激活。然而,还没有CMV特异性TRM细胞的研究。
使用天然小鼠疱疹病毒,小鼠(M)CMV,我们的数据表明,许多MCMV特异性TRM细胞,
在唾液腺和乳腺中发展-已知HCMV和MCMV在这两个部位发生。
棚更广泛地说,唾液腺和乳腺是几种人类疱疹病毒感染的两个部位。
都脱落了TRM细胞的个体发育和功能尚不清楚,这一差距是至关重要的,因为这些T细胞
细胞处于最佳位置,并且可能是控制疱疹病毒再活化的关键。此外,促进
这种“第一反应者”-位于病原体入侵部位的细胞-是CMV的主要优势,
接种疫苗。目的1:我们将确定MCMV特异性TRM细胞是否控制病毒潜伏期,
引发TRM形成的疫苗是否会限制病毒复制。目的2:重复抗原识别
和局部细胞因子环境被认为调节TRM的发展。关键是,感染了
传播缺陷型<$gL-MCMV不能传播到唾液腺,增加了唾液腺的形成,
腺MCMV特异性TRM细胞,这意味着病毒复制或T细胞的重复抗原识别
对抗TRM的发展。我们将使用一系列重组的
病毒目标3:我们的初步数据表明,循环中的记忆膨胀是由病毒竞争驱动的。
抗原的成功竞争的T细胞会膨胀;那些未能竞争的T细胞则不会。值得注意的是,我们的数据
提示MCMV特异性TRM细胞富集了不经历记忆膨胀的T细胞。因此我们
将确定不能竞争MCMV抗原的T细胞是否优先富集在TRM库中。
总之,这些实验将确定MCMV特异性TRM细胞的个体发育和功能,
在疱疹病毒脱落的关键粘膜部位。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher M Snyder其他文献
Christopher M Snyder的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher M Snyder', 18)}}的其他基金
An animal model for cytomegalovirus-induced pathology in the developing retina
发育中视网膜中巨细胞病毒诱导病理学的动物模型
- 批准号:
10432947 - 财政年份:2022
- 资助金额:
$ 18.21万 - 项目类别:
An animal model for cytomegalovirus-induced pathology in the developing retina
发育中视网膜中巨细胞病毒诱导病理学的动物模型
- 批准号:
10559671 - 财政年份:2022
- 资助金额:
$ 18.21万 - 项目类别:
T cell control of MCMV and tissue-localized immune suppression
T 细胞对 MCMV 的控制和组织局部免疫抑制
- 批准号:
10579272 - 财政年份:2020
- 资助金额:
$ 18.21万 - 项目类别:
T cell control of MCMV and tissue-localized immune suppression
T 细胞对 MCMV 的控制和组织局部免疫抑制
- 批准号:
10348755 - 财政年份:2020
- 资助金额:
$ 18.21万 - 项目类别:
Selection of inflationary and tissue-resident T cells during MCMV infection
MCMV 感染期间膨胀和组织驻留 T 细胞的选择
- 批准号:
8986152 - 财政年份:2014
- 资助金额:
$ 18.21万 - 项目类别:
Selection of inflationary and tissue-resident T cells during MCMV infection
MCMV 感染期间膨胀和组织驻留 T 细胞的选择
- 批准号:
9198197 - 财政年份:2014
- 资助金额:
$ 18.21万 - 项目类别:
Selection of inflationary and tissue-resident T cells during MCMV infection
MCMV 感染期间膨胀和组织驻留 T 细胞的选择
- 批准号:
8786495 - 财政年份:2014
- 资助金额:
$ 18.21万 - 项目类别:
Selection of inflationary and tissue-resident T cells during MCMV infection
MCMV 感染期间膨胀和组织驻留 T 细胞的选择
- 批准号:
8690204 - 财政年份:2013
- 资助金额:
$ 18.21万 - 项目类别:
Synergy between BRAF inhibition, tumor-localized T cells and a persistent vaccine
BRAF 抑制、肿瘤定位 T 细胞和持久性疫苗之间的协同作用
- 批准号:
8635992 - 财政年份:2013
- 资助金额:
$ 18.21万 - 项目类别:
Synergy between BRAF inhibition, tumor-localized T cells and a persistent vaccine
BRAF 抑制、肿瘤定位 T 细胞和持久性疫苗之间的协同作用
- 批准号:
8486040 - 财政年份:2013
- 资助金额:
$ 18.21万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 18.21万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 18.21万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 18.21万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 18.21万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 18.21万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 18.21万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 18.21万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 18.21万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 18.21万 - 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 18.21万 - 项目类别:














{{item.name}}会员




